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Role of increased oxygen free radical activity in the pathogenesis of
uremic hypertension. Earlier studies have demonstrated increased oxygen
free radical (OFR) activity, diminished antioxidant capacity and reduced
OFR-inactivating enzymes in chronic renal failure (CRF). Via inactivation
of nitric oxide (NO), oxidation of arachidonic acid and a direct vasocon-
strictive action, OFR can potentially raise blood pressure (BP). This study
was designed to test the hypothesis that increased OFR activity may
contribute to CRF hypertension. Four weeks after 5/6 nephrectomy rats
were treated for two weeks with either lazaroid, a potent antioxidant and
lipid peroxidation inhibitor (CRF-LZ group), or vehicle alone (CRF
group) by daily gastric gavage. The control group was sham operated and
placebo treated. The CRF group exhibited significant increases in BP and
plasma lipid peroxidation product, malondialdehyde (MDA), indicating
enhanced OFR activity. This was accompanied by decreased urinary
nitrate/nitrite (NOx) excretion suggesting depressed NO production. LZ
therapy normalized plasma MDA and significantly ameliorated CRF-
induced hypertension. Both MDA and blood pressure (BP) rose to values
seen in the untreated CRF group within two weeks after termination of
LZ therapy. Intravenous administration of the hydroxyl radical scavenger,
dimethylthiourea (DMTU), significantly lowered BP and raised urinary
NOx excretion. However, no discernible effects were found with either
superoxide dismutase or catalase (superoxide and H2O2 quenchers). The
results suggest that increased OFR activity is, in part, responsible for
CRF-associated HTN. The study further points to hydroxyl radicals as the
major source of OFR in CRF animals. If substantiated in humans,
antioxidant therapy becomes a logical adjunct in the management of CRF.
Several earlier studies have revealed evidence of increased
oxygen free radical (OFR) activity and depressed antioxidant
capacity in chronic renal failure (CRF). Evidence for increased
OFR activity in these studies was based on elevation of plasma
lipid peroxidation product, malondialdehyde (MDA) [1–3], to-
gether with depressed antioxidant capacity and impaired antioxi-
dant enzyme system [4–7] in patients with CRF. For instance,
activities of superoxide dismutase (SOD, a superoxide quencher),
catalase (a H2O2 quencher) and glutathione peroxidase are
markedly diminished in erythrocytes from CRF patients [4–7].
The mechanism of increased OFR activity in CRF is not entirely
clear. Possible mechanisms include increased OFR generation,
decreased OFR inactivation (due to decreased antioxidant capac-
ity) or a combination thereof. Increased OFR activity is believed
to be involved in shortened erythrocyte lifespan and the associ-
ated anemia in CRF [4].
Hypertension (HTN) is a common complication of CRF.
Several factors are involved in the genesis of CRF-induced HTN.
Extracellular fluid volume expansion, increased sympathetic ac-
tivity, elevated endothelin production, enhanced systemic or local
renin-angiotensin system activity, high basal cytosolic [Ca21],
depressed cytosolic [Mg21], accumulation of Na,K-ATPase inhib-
itors and erythropoietin therapy variably contribute to CRF-
induced HTN [8–21]. However, the possible role of increased
OFR activity in the pathogenesis of CRF-induced HTN has not
been elucidated.
Increased OFR activity can potentially elevate blood pressure
by a variety of mechanisms. First, by inactivating nitric oxide
(NO), OFR can reduce NO availability to vascular smooth muscle
and, thereby, raise systemic vascular resistance [22–25]. Second,
by oxidizing arachidonic acid within the cell membrane, OFR can
lead to generation of vasoconstrictive metabolites which can raise
vascular resistance [26–29]. Third, OFR have a direct vasocon-
strictive property [30–32]. In addition, increased OFR activity can
cause cellular injury, promote fibrosis, cellular proliferation and
formation of atherogenic oxidized lipoproteins. In a recent study
we demonstrated a marked increase in OFR activity in rats with
lead-induced HTN [33]. We further showed that administration of
the potent antioxidant and lipid peroxidation inhibitor, lazaroid,
significantly lowered blood pressure while restoring normal OFR
activity in these animals. Based on these observations, we con-
cluded that lead-induced HTN is at least, in part, due to elevated
OFR activity [33]. The present study was designed to test the
hypothesis that elevated OFR activity may, in part, contribute to
CRF-induced HTN. The results showed that OFR activity is
increased in rats with experimental CRF and that administration
of OFR scavenger, lazaroid, improves the associated HTN while
reducing the OFR activity, hence supporting the original hypoth-
esis.
METHODS
Animal models
Male Sprague-Dawley rats (Harlan Sprague Dawley, Inc., In-
dianapolis, IN, USA) with an average weight of 250 g were used.
The animals were housed in a climate-controlled, light-regulated
space with 12-hour light ($500 lux) and dark (,5 lux) cycles. They
were allowed free access to a low nitrate basic diet (Purina Mills,
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Brentwood, MO, USA) and water. The animals were randomly
assigned to the following groups.
The CRF groups underwent surgical resection of the upper and
lower thirds of the left kidney followed by right nephrectomy four
days later. The procedures were carried out under general anes-
thesia (pentobarbital, 50 mg/kg, i.p.) extraperitoneally using a
dorsal incision. Strict hemostasis and aseptic measures were
observed. The CRF animals were subdivided into placebo-treated
(CRF) and lazaroid-treated (CRF-LZ) groups. The CRF-LZ
group was given lazaroid (des-methyl-tirilazad, U-74389G; Up-
john Inc., Kalamazoo, MI, USA), 10 mg/kg twice daily by gastric
gavage for two weeks beginning at week 4. The CRF group
received the vehicle instead. The animals were then observed for
two weeks after the completion of lazaroid and placebo therapies.
The control group was sham operated and received placebo
treatment. A minimum of six animals were included in each
group.
Blood samples were obtained by orbital sinus puncture and
four-hour urine collections were carried out over crushed ice in
individual metabolic cages at different intervals.
Additional subgroups of six CRF and six control animals were
used for assessment of response to intravenous administration of
superoxide dismutase (SOD), catalase and dimethylthiourea
(DMTU), which were used as scavengers of superoxide, hydrogen
peroxide and hydroxyl radicals, respectively.
Measurement of blood pressure
Conscious rats were placed in a restrainer on a heated pad and
allowed to rest inside the cage for fifteen minutes prior to blood
pressure measurements. The procedure was carried out in a
climate-controlled room with an ambient temperature of 70°F.
Rat tails were placed inside a tail cuff, and the cuff was inflated
and released several times to allow conditioning of the animal to
the procedure. Several blood pressure measurements (four con-
secutive readings) were taken by a rat tail sphygmomanometer
attached to a student oscillograph (Harvard Apparatus, South
Natick, MA, USA) and averaged for presentation.
Sequential infusions of oxygen free radical scavengers
Rats were anesthetized with an intraperitoneal injection of 100
mg/kg thiobutabarbital (Research Biochemical International,
Natick, MA, USA) and were placed on a heated pad to maintain
body temperature at 37°C. A tracheotomy was performed, and a
PE-240 catheter was placed in the trachea. A PE-90 catheter with
a flared tip was placed in the bladder for urine collection. PE-50
catheters were placed in the left carotid artery for direct blood
pressure measurement and blood collection and in both jugular
veins for intravenous infusion. An intravenous infusion of 0.5
ml/100 g body wt per hour of a solution of 2.5% albumin was
started and continued for the duration of the experiment. Saline
or drugs were infused at a rate of 0.2 ml/100 g body wt/hour. After
60-minutes of equilibration, a 30-minute control period with
saline infusion was undertaken. At this time, rats were initially
given a bolus injection (37,000 U) of superoxide dismutase (SOD;
Sigma Chemical Co., St. Louis, MO, USA) followed by a contin-
ual infusion of 1,200 U for 30 minutes. After a 30-minute washout
period with saline infusion, the animals were given a bolus
injection of catalase (2 mg/kg; Sigma Chemical Co.) followed by a
30 minute infusion at 1 mg/kg/min. This was followed by a repeat
saline infusion for 30 minutes. Finally, the animals were treated
with bolus injection of DMTU (250 mg/kg; Sigma Chemical Co.)
that was followed by a 30-minute infusion at 8 mg/kg/min. Urine
samples were collected in sterilized containers over ice during the
last 15 minutes of each infusion period. Blood samples (0.4 ml)
were withdrawn from the carotid artery at the middle of each
15-minute clearance period.
Measurements of plasma and urine nitrate/nitrite (NOx)
The amount of total nitrate (NO2) and nitrite (NO3) in the test
samples was determined by a modification of the procedure
described by Braman and Hendrix [34] using the purge system of
a Sievers Instruments Model 270B Nitric Oxide Analyzer (NOA
228; Sievers Instruments Inc., Boulder, CO, USA). Briefly, plasma
samples were first deproteinized using chilled 100% ethanol
(plasma/ethanol 5 1⁄2 vol/vol) before use. The urine samples were
diluted ten times in distilled water prior to analysis. A saturated
solution of VCl3 in 1 M HCl was prepared and filtered prior to use.
Five milliliters of this reagent were added to the purge vessel and
purged with nitrogen gas for 5 to 10 minutes prior to use. The
purge vessel was equipped with a cold water condenser and a
water jacket to permit heating of the reagent to 95°C using a
circulating water bath. The hydrochloric acid vapors were re-
moved by a gas bubbler containing ;15 ml of 1 M NaOH. The gas
flow rate into the chemiluminescence detector was controlled
using a needle valve adjusted to yield a cell pressure of ;7 torr.
The flow rate of nitrogen into the purge vessel was adjusted to
prevent vacuum distillation of the reagent.
Samples were injected into the purge vessel to react with the
VCl3/HCl reagent which converted nitrate, nitrite and S-nitroso
compounds to NO. The NO produced was stripped from the
reaction chamber (by purging with nitrogen and vacuum) and
detected by ozone-induced chemiluminescence in the chemilumi-
nescence detector. The signal generated (NO peak and peak area)
was recorded and processed by a Hewlett Packard Model 3390
Integrator. In a typical assay, 5 ml of the test sample were injected
to the purge vessel, and all samples were run in triplicate [35].
A standard curve was constructed using various concentrations
of NO3
2 (5 to 100 mM) relating the luminescence produced to the
given NO3
2 concentrations of the standard solutions. The amount
of NO2
2/NO3
2 (NOx) in the test sample was determined by
interpolation of the result into the standard curve. The inter- and
intra-assay coefficients of variation for this test are 5.91% and
4.59%, respectively.
Plasma malondialdehyde assay
Lipoperoxides in plasma were determined by HPLC measure-
ment of malondialdehyde-thiobarbituric acid (MDA-TBA) using
a modification of the method of Wong et al [36]. Briefly, a 50 ml
aliquot of plasma was mixed with 0.75 ml 0.44 M H3PO4, 0.25 ml
aqueous 42 mM TBA and 0.45 ml H2O. The mixture was heated in
a boiling water bath for 60 minutes. After cooling on ice, an equal
volume of alkaline methanol (50 ml methanol 1 4.5 ml 1 N
NaOH) was added and centrifuged with a microcentrifuge for five
minutes. Supernatant (50 ml) was then injected into HPLC
(SP8700; Spectra-Physics, San Jose, CA, USA) by a manually-
operated injector. An econosphere C18 column 5 m, 4.6 3 250
mm (Alltech Inc., Deerfield, IL, USA), and a guard column, 3.9 3
2.3 mm, packed with mBondapak Corasil C18 (37 to 50 mm
particle diameter) were used. Mobile phase was a mixture of 50
mM phosphate buffer, pH 6.8, (600 ml) and methanol (400 ml).
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The flow rate was set at 1 ml/min and was monitored with a UV
detector at 532 nm. The peak retention time was 2.9 6 0.15
minutes. The concentration of plasma MDA was determined by
interpolation of peak area into an SP4270 integrator (Spectra-
Physics), which was calibrated with a tetramethoxypropane stan-
dard.
Data presentation and analysis
Data are presented as mean 6 SEM. Analysis of variance
(ANOVA), multiple range test, Student’s t-test and regression
analysis were used as appropriate. P values equal to or less than
5% were considered significant.
RESULTS
The overall data are depicted in Figure 1. As expected, the CRF
group showed a significant rise in serum creatinine concentration
and a significant fall in glomerular filtration rate as estimated by
creatinine clearance (P , 0.001 vs. the control group). This was
accompanied by a significantly lower weight gain in the CRF
group as compared to that seen in the control group at the
conclusion of the study period (P , 0.003). In addition, CRF
animals exhibited a significant fall in hematocrit during the study
period. Administration of lazaroid for the given period did not
significantly affect creatinine clearance or body wt. However,
lazaroid administration resulted in a slight but significant reduc-
tion in hematocrit.
Blood pressure
Figure 2 illustrates the blood pressure results in the experi-
ments. The CRF group exhibited a steady rise in blood pressure
that peaked at week 6 and plateaued thereafter. In contrast, blood
pressure remained practically unchanged in the control group
throughout the study period. Lazaroid administration led to a
significant fall in arterial blood pressure in the CRF-LZ group as
compared to the placebo-treated CRF group (P , 0.01). How-
ever, LZ therapy did not completely reverse the associated HTN.
After the cessation of lazaroid therapy, blood pressure rose to a
value which approached that seen in the placebo-treated CRF
animals within two weeks.
Plasma malondialdehyde values
The values for plasma MDA are illustrated in Figures 2 and 3.
The CRF group showed an impressive twofold rise in plasma
MDA concentration indicating increased OFR activity. Lazaroid
administration completely normalized plasma MDA in the
CRF-LZ group. However, following cessation of lazaroid therapy,
plasma MDA gradually increased toward the pretreatment values.
A significant direct correlation was found between plasma MDA
concentration and arterial blood pressure in the study animals
(r 5 0.67, P , 0.005). Similarly, blood pressure measurements
obtained in the CRF-LZ group before, during and two weeks after
completion of lazaroid therapy directly correlated with the corre-
sponding MDA measurements (r 5 0.57, P , 0.05).
Plasma and urinary nitrite
Figure 4 depicts the NOx values over time. The CRF group
exhibited a marked threefold reduction in urinary NOx excretion
reflecting a reduction in total body NO production. No significant
difference was found in plasma NOx concentration in the study
groups. Lazaroid therapy did not significantly alter either plasma
NOx concentration or urinary NOx excretion.
Fig. 1. Hematocrit, body weight, plasma
creatinine concentration and creatinine
clearance obtained at the end of the study
period in the normal control group (M),
placebo-treated CRF group (p), and lazaroid-
treated CRF animals (s). N 5 6 animals in
each group. *P , 0.05 versus control (Duncan’s
multiple range test). #P , 0.05 versus CRF
group (Duncan’s multiple range test).
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Response to administration of oxygen free radical scavengers
Data are shown in Figure 5. Intravenous administration of SOD
failed to alter mean arterial blood pressure in either the CRF or
the normal control group. Likewise, SOD administration had no
effect on urinary NOx excretion in the two groups. In addition,
plasma NO concentration was not changed by SOD (data not
shown). Similarly, SOD did not alter glomerular filtration rate
measured as creatinine clearance (data not shown).
As with SOD, i.v. administration of catalase did not affect
either blood pressure, plasma NOx concentration or urinary NOx
excretion. Likewise, catalase did acutely change glomerular filtra-
tion rate.
In contrast to SOD and catalase, i.v. administration of DMTU
led to a marked fall in arterial blood pressure in the CRF animals.
Although DMTU administration resulted in a significant decline
in arterial blood pressure in the control group (28 mm Hg), the
magnitude of DMTU-induced fall in blood pressure was nearly
fourfold greater in the CRF animals (231 mm Hg). In addition,
DMTU administration led to an approximately threefold rise in
urinary NOx excretion together with an about twofold increase in
plasma NOx concentration (plasma NOx not shown). These
findings suggest that DMTU raises total body NO production in
both normal and CRF animals. However, DMTU had no effect on
glomerular filtration rate.
Fig. 2. Tail systolic arterial blood pressure and plasma concentrations of
lipid peroxidation product, malondialdehyde (MDA) before, during and
after placebo or lazaroid therapies in the placebo-treated CRF group and
lazaroid-treated CRF animals, respectively. Also included are data ob-
tained in the normal control group. N 5 6 animals in each group. Symbols
are: (M) CRF-placebo; (E) CRF-lazaroid; (L) normal. *P , 0.05 versus
control group (ANOVA and Duncan’s multiple range test); #P , 0.05
versus CRF group (ANOVA and Duncan’s multiple range test).
Fig. 3. Correlation between arterial blood pressure in the entire study
groups (A) and the lazaroid-treated group before, during and two weeks
after completion of lazaroid therapy (B). Symbols are: (M) CRF-placebo;
(E) CRF-lazaroid; (L) normal; (F) lazaroid. In A, r 5 0.677, P , 0.005;
in B, r 5 0.573; P , 0.05.
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DISCUSSION
The CRF animals employed in the present study showed a
marked elevation of plasma lipid peroxidation product, MDA,
indicating increased OFR activity. This observation is in confor-
mity with the results of the earlier studies of humans with CRF
[1–3]. The elevation of MDA in the CRF animals was accompa-
nied by a marked rise in arterial blood pressure and a significant
decline in urinary excretion of NO metabolites (NOx). The latter
finding is consistent with our earlier observation in this model
[37]. As noted in the introduction, increased OFR activity can
potentially cause HTN by a number of different mechanisms. In
view of the reported elevation of OFR activity, depressed OFR-
inactivating-enzyme systems and reduced antioxidant capacity in
clinical CRF [1–7], we hypothesized that CRF-associated HTN
may be, in part, due to excess OFR activity. We further assumed
that if the above hypothesis is true, restoration of OFR to the
normal values by administration of an exogenous antioxidant and
lipid peroxidation inhibitor should improve the OFR-mediated
component of CRF HTN. The present study was designed to test
this hypothesis. The study showed a concurrence of HTN with
elevated OFR activity in CRF animals. Administration of the
potent antioxidant and lipid peroxidation inhibitor, des-methyl-
tirilazad, for two weeks normalized plasma MDA concentration
and, hence, OFR activity in the CRF-LZ group. The reduction in
OFR activity was accompanied by a marked but partial amelio-
ration of CRF-associated HTN. Discontinuation of lazaroid ther-
apy led to a rise in both blood pressure and OFR activity towards
pretreatment values during the ensuing follow-up period, thus
providing strong evidence in support of a causal relationship
between elevated OFR activity and hypertension in CRF animals.
This supposition is further supported by the presence of a
significant direct correlation between plasma MDA and arterial
blood pressure values obtained before, during and after lazaroid
therapy in the CRF-LZ group. Similarly, the two parameters
showed a strongly positive correlation when values obtained in all
study groups were considered.
It is interesting that urinary NOx excretion remained low during
Fig. 4. Plasma concentration and urinary excretion of total nitrate/
nitrite (NOx) in the normal control group, placebo-treated CRF (CRF-
PL) group and lazaroid-treated CRF (CRF-LZ) group. N 5 6 animals in
each group. *P , 0.001 versus control group (ANOVA and Duncan’s
multiple range test).
Fig. 5. Change in intra-arterial blood pressure from baseline and uri-
nary excretion of total nitrates/nitrites (NOx) in response to intravenous
infusions of superoxide dismutase (SOD), a superoxide quencher, cata-
lase (CAT), a H2O2 quencher, and the hydroxyl radical scavenger,
dimethylthiourea (DMTU), in normal control (M) and CRF (s) groups.
N 5 6 animals in each group. *P , 0.05 (Student’s t-test CRF vs. control).
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and after lazaroid therapy, suggesting that correction of CRF-
associated excess OFR activity with lazaroid therapy does not
reverse the CRF-associated reduction in total body NO produc-
tion. It should be noted, however, that lazaroid therapy may have
increased NO availability to vascular smooth muscle by mitigating
NO inactivation (oxidation) by OFR. This process, per se, can
contribute to improvement in vasodilatory tone and blood pres-
sure without a true increase in NO production.
Having demonstrated the possible role of excess OFR activity,
we then attempted to estimate the approximate contribution of
different OFR species to the overall increased OFR activity and
HTN in CRF. To this end, we studied a separate set of CRF and
control animals using intravenous injections of the superoxide
quencher (SOD), H2O2 quencher (catalase), as well as DMTU,
which is a hydroxyl radical and to a lesser extent a superoxide
scavenger. The results showed no significant response in blood
pressure to either SOD or catalase in either CRF or the control
group. This observation suggests, although it does not prove, that
superoxide and H2O2 may not directly account for increased OFR
activity in CRF animals. It should be noted that lack of discernible
response to these enzymes may reflect their enhanced inhibition
and/or elimination in CRF. Further studies are required to
explore these possibilities.
In contrast to SOD and catalase, DMTU administration was
followed by a significant reduction in arterial blood pressure in
CRF and to a much lesser extent in the controls animals. The
magnitude of the hypotensive response to DMTU in the CRF
group was about fourfold greater than that seen in the normal
control group. This observation suggests that increased OFR
activity in CRF may be predominantly due to the presence of
excess hydroxyl radicals. Further studies are required to substan-
tiate this possibility using more direct quantitation of hydroxyl
radical activity that is currently unavailable to us. Interestingly,
DMTU administration resulted in a marked increase in urinary
excretion and plasma concentration of NOx, suggesting enhanced
total body NO production. The mechanism by which DMTU
increased NO production in both normal and CRF animals is
uncertain and requires further investigation. It is not clear as to
whether the stimulatory action of DMTU is due to the NOS-
inhibitory effect of OFR (specifically, hydroxyl radicals) or an
OFR-independent direct or indirect effect of the drug. Whatever
the mechanism, the rapidity of action of DMTU on NO produc-
tion suggests that its initial action involves activation of preformed
constitutive NOS as opposed to stimulation of NOS gene tran-
scription and protein synthesis, which would have led to a delayed
response. In any case, enhanced NO production no doubt con-
tributed to the hypotensive response observed with DMTU ad-
ministration.
That the CRF-LZ group showed a slight but significant reduc-
tion in hematocrit as compared with the placebo-treated CRF
animals is interesting. The available data do not permit a defini-
tive conclusion concerning the possible mechanism(s) involved in
this process. The slight difference in hematocrit did not appear to
be due to severity of illness, blood loss or nutritional factors. This
is because there was no difference in surgical blood loss, food
intake, renal function, physical activity or behavior between
placebo-treated and lazaroid-treated CRF animals. Whatever the
mechanism, the slight reduction in hematocrit is unlikely to have
contributed to the marked amelioration of CRF-associated hyper-
tension with antioxidant therapy. This is because: (1) chronic
anemia does not usually lower systolic blood pressure even though
it tends to widen pulse pressure by lowering diastolic pressure.
Blood pressure values given here are systolic measurements that
are usually unaltered or even slightly raised by anemia. (2) While
statistically significant, the numerical difference in mean hemat-
ocrit values between the CRF and CRF-LZ group was quite small
(;2%). In contrast, the effect on CRF-induced hypertension was
quite marked and could not be accounted for by the small
variation in hematocrit between the two groups. In fact, we have
shown that much larger fluctuations in hematocrit caused by iron
deficiency and its subsequent correction by iron repletion do not
appreciably alter blood pressure in patients with end-stage renal
disease [38]. Moreover, we have recently shown that, contrary to
the conventional belief, erythropoietin-induced HTN is not due to
the rise in hematocrit in rats with experimental CRF [21]. (3) The
hematocrit variations in question (41% to 43%) are within the flat
segment of the hematocrit-viscosity curve and as such have nearly
no effect on viscosity-related vascular resistance. (4) We found a
similar blood pressure lowering effect of lazaroids in rats with
lead-induced hypertension (another condition marked by in-
creased OFR activity) without a concomitant effect on hematocrit
[33]. Based on the above observations, we believe that the marked
effect of antioxidant therapy on uremic hypertension was not
related to minor differences found in hematocrit.
In conclusion, the present study has provided strong evidence
for the possible role of increased oxygen free radical activity in the
pathogenesis of CRF-induced HTN in rats. The study has further
demonstrated the efficacy of antioxidant therapy in this condition.
If confirmed in humans, antioxidant therapy may potentially
become an important adjunct in the management of patients with
chronic renal failure.
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APPENDIX
Abbreviations used in this article are: BP, blood pressure; CRF, chronic
renal failure; DMTU, dimethylthiourea; HTN, hypertension; LZ, lazaroid
therapy; NO, nitric oxide; NOx, nitrate/nitrite; OFR, oxygen free radical;
SOD, superoxide dismutase.
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